TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15613141

Group type: EXPERIMENTAL
Intervention: Pramipexole (PPX)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Pergolide (PRG)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: L-dopa therapy (as part of both interventions)
Number of subjects: 41
Study: 12015621

Group type: EXPERIMENTAL
Intervention: Isolated rupture of the anterior cruciate ligament (group 1)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Rupture of the anterior cruciate ligament and accompanying joint damage (group 2)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 106
Study: 10443307

Group type: EXPERIMENTAL
Intervention: Second harmonic imaging (SHI)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fundamental imaging (FI)
Number of subjects: 30
Study: 8551648

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN) for 2 weeks (group II)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enteral nutrition for 2 weeks (group III)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ad libitum oral diet for 2 weeks (group I)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN) for 2 weeks (group IV)
Number of subjects: 0
Study: 2621333

Group type: EXPERIMENTAL
Intervention: Controlled release salbutamol
Number of subjects: 52

Group type: COMPARATOR
Intervention: Ordinary salbutamol
Number of subjects: 52
Study: 831965

Group type: EXPERIMENTAL
Intervention: Low-dose subcutaneous heparin
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control (no heparin)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control (non-smokers)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control (smokers)
Number of subjects: 78
Study: 30851727

Group type: EXPERIMENTAL
Intervention: Hospital-based multi-intervention (multi, n=30)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard care (stand, n=26)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: T2D patients (n=56)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Non-T2D controls (heart transplant donors, n=147)
Number of subjects: 56
Study: 28603312

Group type: EXPERIMENTAL
Intervention: Community-based interventions (home-based counselling or women’s groups)
Number of subjects: 17
Study: 25497250

Group type: EXPERIMENTAL
Intervention: Resolute stent (Medtronic Inc)
Number of subjects: 1391

Group type: EXPERIMENTAL
Intervention: Xience V stent (Abbott Vascular)
Number of subjects: 1391

Group type: EXPERIMENTAL
Intervention: Bifurcation lesions
Number of subjects: 1391

Group type: COMPARATOR
Intervention: Nonbifurcation lesions
Number of subjects: 1391
Study: 23228946

Group type: EXPERIMENTAL
Intervention: Neutral-valve closed-system connector (Tego Needlefree Hemodialysis Connector)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Trisodium citrate, 46.7%, locking solution (Citra-Lock)
Number of subjects: 66
Study: 20844946

Group type: EXPERIMENTAL
Intervention: Diaphragm and lubricant gel
Number of subjects: 955
Study: 19406608

Group type: EXPERIMENTAL
Intervention: Computer tailored physical activity intervention (n=563)
Number of subjects: 1171

Group type: COMPARATOR
Intervention: Generic non-tailored intervention (n=608)
Number of subjects: 1171
Study: 16753156

Group type: COMPARATOR
Intervention: Control group (current dose of rFSH)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Step-up group (additional 75 IU of rFSH)
Number of subjects: 60
Study: 15153855

Group type: EXPERIMENTAL
Intervention: Altered cast impression procedure
Number of subjects: 72

Group type: COMPARATOR
Intervention: One-piece cast
Number of subjects: 72
Study: 11578889

Group type: EXPERIMENTAL
Intervention: 1% lidocaine, 0.2 mL/kg
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 1.5% lidocaine, 0.2 mL/kg
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 2% lidocaine, 0.2 mL/kg
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 1% lidocaine, 0.3 mL/kg
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 2% lidocaine, 0.3 mL/kg
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 96
Study: 9040451

Group type: EXPERIMENTAL
Intervention: Low blood pressure goal (mean arterial pressure < or = 92 mm Hg)
Number of subjects: 585

Group type: COMPARATOR
Intervention: Usual blood pressure goal (mean arterial pressure < or = 107 mm Hg)
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Low blood pressure goal
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Low blood pressure goal for patients with urinary protein excretion > 1 g/d
Number of subjects: 585
Study: 7935657

Group type: EXPERIMENTAL
Intervention: Fish oil (12 g daily)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo (olive oil, similar dosage)
Number of subjects: 106
Study: 3281724

Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (HDMTX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: RTSC (cranial irradiation and sequentially administered drug pairs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HDMTX
Number of subjects: 0

Group type: COMPARATOR
Intervention: RTSC
Number of subjects: 0
Study: 31706622

Group type: EXPERIMENTAL
Intervention: Calcium Hydroxide (Ca(OH)2)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Calcium Hydroxide (Ca(OH)2) + Ibuprofen
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Calcium Hydroxide (Ca(OH)2) + Ciprofloxacin
Number of subjects: 66
Study: 28271228

Group type: EXPERIMENTAL
Intervention: Oral midazolam syrup 0.5 mg/kg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intranasal midazolam spray 0.2 mg/kg
Number of subjects: 90
Study: 25773607

Group type: EXPERIMENTAL
Intervention: Evolocumab (140 mg every 2 weeks or 420 mg monthly) plus standard therapy
Number of subjects: 4465

Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 4465
Study: 21564309

Group type: EXPERIMENTAL
Intervention: Stretching (dorsiflexion to end ROM and holding for 1 min, five times)
Number of subjects: 11
Study: 20457590

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir 300/100 mg plus omeprazole
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir 400/100 mg plus omeprazole
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily
Number of subjects: 56
Study: 19025944

Group type: EXPERIMENTAL
Intervention: Gadoversetamide (OptiMARK) at doses of 0.05, 0.1, 0.2, or 0.3 mmol/kg
Number of subjects: 577
Study: 17161766

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCT) doses (6.25 mg, 12.5 mg, or 25 mg) and extended release (ER) metoprolol doses (25 mg, 50 mg, 100 mg, 200 mg)
Number of subjects: 1571

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1571
Study: 12705304

Group type: EXPERIMENTAL
Intervention: Immediate functional loading of Brånemark System implants (development group)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 2-stage implants (development group)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Simplified protocol (simplified treatment group)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Prosthesis (both groups)
Number of subjects: 34
Study: 11115260

Group type: EXPERIMENTAL
Intervention: Vitrectomy or tap biopsy for initial management of endophthalmitis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical repair of retinal detachment
Number of subjects: 0

Group type: COMPARATOR
Intervention: No retinal detachment
Number of subjects: 0
Study: 9187435

Group type: EXPERIMENTAL
Intervention: MACOP-B
Number of subjects: 236

Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 236
Study: 1286503

Group type: EXPERIMENTAL
Intervention: Flumazenil (maximum dose, 30 ml providing 3 mg of flumazenil)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Placebo (maximum dose, 30 ml)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Flumazenil (open-label after double-blind phase)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Placebo (open-label after double-blind phase)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 326
Study: 3518019

Group type: EXPERIMENTAL
Intervention: Codeine
Number of subjects: 13
Study: 29952033

Group type: EXPERIMENTAL
Intervention: Two-piece implant system (BRA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: One-piece implant system (STM)
Number of subjects: 60
Study: 27521607

Group type: EXPERIMENTAL
Intervention: Trimethoprim/Sulfamethoxazole (TMP-SMZ) 160 mg/800 mg, 1 tablet twice daily for 45 days, then 1 tablet every 2 days for 311 days
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo (identical tablet containing starch, no active ingredients), 1 tablet every 2 days for 311 days
Number of subjects: 141
Study: 24504700

Group type: EXPERIMENTAL
Intervention: Danirixin 50 mg IR in fed state
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Danirixin 50 mg IR in fasted state
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bioenhanced Formulation 1 in fasted state
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bioenhanced Formulation 2 in fasted state
Number of subjects: 20

Group type: COMPARATOR
Intervention: Omeprazole 20 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bioenhanced formulations
Number of subjects: 20
Study: 21989324

Group type: COMPARATOR
Intervention: Dietary advice alone
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Dietary advice plus FV vouchers (10-40 euros/month)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Dietary advice plus FV vouchers
Number of subjects: 302
Study: 19942479

Group type: EXPERIMENTAL
Intervention: Cetuximab with FOLFOX6 (oxaliplatin, fluorouracil, and folinic acid)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Cetuximab with FOLFIRI (irinotecan, fluorouracil, and folinic acid)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Cetuximab with FOLFOX6
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Cetuximab with FOLFIRI
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: KRAS wild-type tumours
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: KRAS-mutated tumours
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Chemotherapy (with cetuximab)
Number of subjects: 114
Study: 18171954

Group type: EXPERIMENTAL
Intervention: Intramuscular injections of botulinum toxin A combined with hip abduction brace (6 hours/day)
Number of subjects: 90

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 90
Study: 15832334

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation of the dorsolateral prefrontal cortex by single pulses of varying field intensities.
Number of subjects: 3

Group type: COMPARATOR
Intervention: General population controls with a high burden of complaints related to EMF exposure.
Number of subjects: 3

Group type: COMPARATOR
Intervention: General population controls with a low burden of complaints related to EMF exposure.
Number of subjects: 3
Study: 12695416

Group type: EXPERIMENTAL
Intervention: Blood pressure-lowering therapy
Number of subjects: 15

Group type: COMPARATOR
Intervention: No blood pressure-lowering therapy
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Hypertensive subjects with type 2 diabetes
Number of subjects: 15
Study: 10824628

Group type: EXPERIMENTAL
Intervention: Almotriptan with verapamil (120‐mg sustained‐release verapamil tablet twice daily for 7 days and one 12.5‐mg almotriptan tablet on day 7)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Almotriptan alone (one 12.5‐mg almotriptan tablet on day 7)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Almotriptan with verapamil
Number of subjects: 12
Study: 8870755

Group type: EXPERIMENTAL
Intervention: Mannitol (1 g/kg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 44
Study: 1505149

Group type: EXPERIMENTAL
Intervention: 2 mg diazepam
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 5 mg diazepam
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 10 mg diazepam
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (2 mg diazepam)
Number of subjects: 11
Study: 6356329

Group type: EXPERIMENTAL
Intervention: Bicozamycin (500 mg, q.i.d. for 3 days)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulphamethoxazole (160 mg TMP‐SMX 800 mg, b.i.d. for 5 days)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Trimethoprim (200 mg, b.i.d. for 5 days)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo (first trial)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo (second trial)
Number of subjects: 250
Study: 30202072

Group type: EXPERIMENTAL
Intervention: Superonasal (SN) injection
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: Inferonasal (IN) injection
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: Superotemporal (ST) injection
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: Inferotemporal (IT) injection
Number of subjects: 1004
Study: 28528560

Group type: EXPERIMENTAL
Intervention: Health scout intervention utilizing motivational interviewing strategies and a mobile phone-based counseling application.
Number of subjects: 771
Study: 26505342

Group type: EXPERIMENTAL
Intervention: High-dose interferon-α-2b (IFN-α-2b)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group (no high-dose IFN-α-2b)
Number of subjects: 117
Study: 23868265

Group type: EXPERIMENTAL
Intervention: Decompressive surgery
Number of subjects: 64

Group type: COMPARATOR
Intervention: Best medical treatment (Control)
Number of subjects: 64
Study: 20924615

Group type: EXPERIMENTAL
Intervention: Rebamipide (300 mg/day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: NSAID (diclofenac sodium, 75 mg/day) and omeprazole (20 mg/day) with placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Rebamipide co-therapy
Number of subjects: 80
Study: 19177538

Group type: COMPARATOR
Intervention: Facilitated BMD testing
Number of subjects: 220

Group type: COMPARATOR
Intervention: OP case manager intervention
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Usual care
Number of subjects: 220
Study: 17565828

Group type: EXPERIMENTAL
Intervention: Fiber-reinforced posts and composite cores (Group A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Prefabricated titanium alloy posts and composite cores (Group B)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cast nickel-chromium post-cores (Group C)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (cast nickel-chromium post-cores and metal-ceramic crowns)
Number of subjects: 40
Study: 15377321

Group type: EXPERIMENTAL
Intervention: 1000 mg phenazone
Number of subjects: 208

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 208
Study: 15868348

Group type: EXPERIMENTAL
Intervention: Outpatient group living
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Nursing home residents
Number of subjects: 314

Group type: COMPARATOR
Intervention: Home care
Number of subjects: 314

Group type: COMPARATOR
Intervention: Outpatient care or day care
Number of subjects: 314
Study: 10511067

Group type: EXPERIMENTAL
Intervention: Buprenorphine 4 mg/70 kg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Buprenorphine 8 mg/70 kg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Higher dosing regimens (48, 72, 96 hours)
Number of subjects: 14
Study: 7489530

Group type: EXPERIMENTAL
Intervention: nifedipine-GITS 30 mg
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: nifedipine-GITS 60 mg
Number of subjects: 173

Group type: COMPARATOR
Intervention: nifedipine-PA
Number of subjects: 173

Group type: COMPARATOR
Intervention: nifedipine-GITS
Number of subjects: 173
Study: 1722967

Group type: EXPERIMENTAL
Intervention: Low dose iloprost (0.5 ng/kg/min)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Standard dose iloprost (2 ng/kg/min)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both doses
Number of subjects: 55
Study: 6293717

Group type: EXPERIMENTAL
Intervention: Cefotaxime (1 gm, perioperatively and up to 2 hours postoperatively)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Cefotaxime (1 gm, perioperatively and for 24 hours postoperatively)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Cefazolin (1 gm, perioperatively and for 24 hours postoperatively)
Number of subjects: 133
Study: 31865326

Group type: EXPERIMENTAL
Intervention: Group I (1 strength, 10,000 TU/mL)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Group II (standard, 7 injections with 1,000 TU/mL and 10,000 TU/mL)
Number of subjects: 87
Study: 30762267

Group type: EXPERIMENTAL
Intervention: Cuminum cyminum L. (CuEO) essential oil, 75 mg, thrice daily for 8 weeks
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Cuminum cyminum L. (CuEO) essential oil
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo soft gel
Number of subjects: 56
Study: 28378318

Group type: EXPERIMENTAL
Intervention: Anterior approach (AA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional approach (CA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anterior approach (AA) in >5 cm tumors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional approach (CA) in >5 cm tumors
Number of subjects: 0
Study: 27128727

Group type: EXPERIMENTAL
Intervention: Psychoeducational therapy in addition to routine follow-up
Number of subjects: 59

Group type: COMPARATOR
Intervention: Routine follow-up without psychoeducation
Number of subjects: 59
Study: 24613632

Group type: EXPERIMENTAL
Intervention: WDYD intervention (n=456)
Number of subjects: 907

Group type: COMPARATOR
Intervention: Control condition (n=451: no intervention)
Number of subjects: 907

Group type: EXPERIMENTAL
Intervention: WDYD intervention
Number of subjects: 907
Study: 22622651

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided PICC insertion
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (vein visualization and palpation)
Number of subjects: 42
Study: 17882136

Group type: EXPERIMENTAL
Intervention: 20 mg iron and 1 mg riboflavin weekly for 6 months
Number of subjects: 645

Group type: EXPERIMENTAL
Intervention: 20 mg zinc and 1 mg riboflavin weekly for 6 months
Number of subjects: 645

Group type: EXPERIMENTAL
Intervention: 20 mg iron, 20 mg zinc and 1 mg riboflavin weekly for 6 months
Number of subjects: 645

Group type: COMPARATOR
Intervention: Riboflavin alone (control) weekly for 6 months
Number of subjects: 645
Study: 17245230

Group type: EXPERIMENTAL
Intervention: Triple-nucleoside (ZDV/3TC/ABC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3-drug efavirenz (ZDV/3TC + EFV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4-drug efavirenz (ZDV/3TC/ABC + EFV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ZDV/3TC/ABC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All study participants
Number of subjects: 0
Study: 15911866

Group type: EXPERIMENTAL
Intervention: Trastuzumab plus docetaxel
Number of subjects: 186

Group type: COMPARATOR
Intervention: Docetaxel alone
Number of subjects: 186
Study: 11923756

Group type: EXPERIMENTAL
Intervention: Octreotide (100 microg subcutaneous)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (100 mg intravenous)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Placebo (normal saline solution)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: All groups (Octreotide, Hydrocortisone, Placebo)
Number of subjects: 340
Study: 9872337

Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate/tretinoin gel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clindamycin HCl/tretinoin gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clindamycin phosphate lotion (1% clindamycin; Dalacin T)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate/tretinoin gel in acne patients
Number of subjects: 0
Study: 7613151

Group type: EXPERIMENTAL
Intervention: Allergen injection immunotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical corticosteroids
Number of subjects: 0
Study: 31494047

Group type: EXPERIMENTAL
Intervention: Chest Computed Tomography (CT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Chest Radiography (CR)
Number of subjects: 36
Study: 31008759

Group type: EXPERIMENTAL
Intervention: Injection of autologous platelet-rich plasma and fibrin glue (PRP-FG) into the wound after wide excision of the sinus with primary closure
Number of subjects: 40

Group type: COMPARATOR
Intervention: Wide excision of the sinus with primary closure (Control group)
Number of subjects: 40
Study: 27056207

Group type: EXPERIMENTAL
Intervention: TAP block
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (general anaesthesia alone)
Number of subjects: 58
Study: 26112050

Group type: COMPARATOR
Intervention: Usual follow-up visits and aftercare provided in secondary care
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual follow-up visits and aftercare provided in secondary care with additional use of Oncokompas(2.0)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Follow-up and aftercare in primary care
Number of subjects: 300

Group type: COMPARATOR
Intervention: Follow-up and aftercare in primary care with additional use of Oncokompas(2.0)
Number of subjects: 300
Study: 23480640

Group type: EXPERIMENTAL
Intervention: Once-daily darunavir/ritonavir (DRV/r) 800/100 mg
Number of subjects: 590

Group type: COMPARATOR
Intervention: Twice-daily darunavir/ritonavir (DRV/r) 600/100 mg
Number of subjects: 590
Study: 20627942

Group type: EXPERIMENTAL
Intervention: Slow infusion of antithrombin concentrate (100 IU/min) before full-dose heparinisation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fast infusion of antithrombin concentrate (250 IU/min)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both groups (slow and fast infusion)
Number of subjects: 40
Study: 17091331

Group type: EXPERIMENTAL
Intervention: High-dose adjuvant chemotherapy (mitomycin and tegafur-uracil)
Number of subjects: 1410

Group type: COMPARATOR
Intervention: Low-dose adjuvant chemotherapy (mitomycin and tegafur-uracil)
Number of subjects: 1410
Study: 15602113

Group type: EXPERIMENTAL
Intervention: 30 mg paroxetine
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 12145379

Group type: EXPERIMENTAL
Intervention: Self-management of incontinence
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Attribution of incontinence to aging
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Perception that incontinence restricted activities
Number of subjects: 74
Study: 12080675

Group type: EXPERIMENTAL
Intervention: Tianlong xifeng granule (TXG)
Number of subjects: 412

Group type: COMPARATOR
Intervention: Xixian tongshuan pill (XTP)
Number of subjects: 412